RT Journal Article
SR Electronic
T1 Evidence of recent Epstein-Barr virus reactivation in individuals experiencing Long COVID
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.21.22276660
DO 10.1101/2022.06.21.22276660
A1 Michael J. Peluso
A1 Tyler-Marie Deveau
A1 Sadie E. Munter
A1 Dylan Ryder
A1 Amanda Buck
A1 Scott Lu
A1 Sarah A. Goldberg
A1 Rebecca Hoh
A1 Viva Tai
A1 Leonel Torres
A1 Nikita S. Iyer
A1 Monika Deswal
A1 Lynn H. Ngo
A1 Melissa Buitrago
A1 Antonio Rodriguez
A1 Jessica Y. Chen
A1 Brandon C. Yee
A1 Ahmed Chenna
A1 John W. Winslow
A1 Christos J. Petropoulos
A1 Amelia N. Deitchman
A1 Peter W. Hunt
A1 Matthew S. Durstenfeld
A1 Priscilla Y. Hsue
A1 J. Daniel Kelly
A1 Jeffrey N. Martin
A1 Steven G. Deeks
A1 Timothy J. Henrich
YR 2022
UL http://medrxiv.org/content/early/2022/06/22/2022.06.21.22276660.abstract
AB Epstein-Barr virus (EBV) reactivation has been proposed as a driver of Long COVID (LC), but studies in well- characterized post-acute COVID-19 cohorts of individuals with and without Long COVID symptoms over a time course consistent with current case definitions of LC are limited. In a cohort of 294 hundred adults with a history of SARS-CoV-2 infection, we observed that LC symptoms such as fatigue and neurocognitive dysfunction at a median of 4 months following initial diagnosis were associated with serological evidence of recent EBV reactivation (early antigen-D IgG positivity or nuclear antigen IgG levels >600 U/mL), but not with ongoing EBV viremia.. Importantly, Long COVID was also observed in the small proportion without evidence of prior or recent EBV infection, suggesting that EBV reactivation is not a prerequisite for this condition. Overall, these findings expand our knowledge of the relationships between EBV reactivation and LC and suggest that further assessment during the acute phase of COVID-19 is warranted.SUMMARY The authors found that Long COVID symptoms in a post-acute cohort were associated with serological evidence of recent EBV reactivation when adjusted for participant factors, sample timing, comorbid conditions and prior hospitalization, but not with ongoing presence of EBV viremia.Competing Interest StatementAC, BCY, JWW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCoSGD reports grants and/or personal fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences outside the submitted work. TJH reports consulting for Roche and Regeneron, and grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work. The remaining authors report no conflicts. Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID 3R01AI141003-03S1 [to TJ Henrich] and by the Zuckerberg San Francisco Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent. The study was approved by the Institutional Review Board at the University of California, San Francisco.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.